Allogene Sets 25–30% MRD Clearance Goal for April ALPHA3 Readout
Allogene Therapeutics expects an April readout from its ALPHA3 frontline consolidation trial, evaluating off-the-shelf cema-cel in MRD-positive LBCL patients with 12 subjects per arm. The study targets a 25–30% absolute improvement in MRD clearance at day 45 versus a projected 20% spontaneous clearance rate.
1. Trial Design and Patient Population
The ALPHA3 study enrolls newly diagnosed large B-cell lymphoma patients who achieve remission after standard frontline therapy. MRD-positive subjects, identified via ultrasensitive ctDNA PCR, are randomized to either observation or an infusion of off-the-shelf cema-cel, with 12 patients in each arm and roughly half of sites in community settings.
2. Integration of MRD Testing
Allogene partners with Foresight (now part of Natera) to perform circulating tumor DNA assays that detect residual disease beyond imaging. This MRD-driven enrollment ensures only patients with molecular relapse risk are treated, leveraging an outpatient-friendly workflow including lymphodepletion and infusion clinic administration.
3. Futility Analysis and Clearance Targets
The company set a futility threshold aiming for a 25–30% absolute difference in MRD clearance rates between cema-cel and observation arms, versus an expected 20% spontaneous clearance in the control group. Stakeholders may view deltas near 11% as insufficient to justify therapy adoption.
4. April Readout Expectations and Safety
Initial data to be reported in April will compare MRD-negative conversion at day 45 post-randomization and include preliminary safety profiles. Emphasis is placed on outpatient administration metrics and monitoring for cytokine release syndrome and neurotoxicity in this remission-stage population.